# Alberto J. Montero

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/alberto-j-montero/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,073 |
| Field | Breast Cancer Treatment Studies |
| h-index | 44 |
| i10-index | 110 |
| Last Known Institution | University Hospitals of Cleveland |
| OpenAlex ID | https://openalex.org/A5024618610 |
| ORCID iD | 0000-0002-8221-8120 |
| Works | 336 |

## Researcher papers

- [Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy](https://scholariq.org/papers/increased-circulating-myeloid-derived-suppressor-cells-correlate-with-clinical/)
- [Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial](https://scholariq.org/papers/elacestrant-oral-selective-estrogen-receptor-degrader-versus-standard-endocrine/)
- [A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells](https://scholariq.org/papers/a-human-promyelocytic-like-population-is-responsible-for-the-immune-suppression/)
- [Docetaxel for treatment of solid tumours: a systematic review of clinical data](https://scholariq.org/papers/docetaxel-for-treatment-of-solid-tumours-a-systematic-review-of-clinical-data/)
- [Novel HER2–targeted therapies for HER2–positive metastatic breast cancer](https://scholariq.org/papers/novel-her2-targeted-therapies-for-her2-positive-metastatic-breast-cancer/)
- [Myeloid-derived Suppressor Cells in Cancer Patients](https://scholariq.org/papers/myeloid-derived-suppressor-cells-in-cancer-patients/)
- [Molecular Profiling for Breast Cancer: A Comprehensive Review](https://scholariq.org/papers/molecular-profiling-for-breast-cancer-a-comprehensive-review/)
- [Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer](https://scholariq.org/papers/cellular-redox-pathways-as-a-therapeutic-target-in-the-treatment-of-cancer/)
- [Treating Breast Cancer in the 21st Century: Emerging Biological Therapies](https://scholariq.org/papers/treating-breast-cancer-in-the-21st-century-emerging-biological-therapies/)
- [Myeloid-Derived Suppressor Cells in Cancer: Therapeutic, Predictive, and Prognostic Implications](https://scholariq.org/papers/myeloid-derived-suppressor-cells-in-cancer-therapeutic-predictive-and-prognostic/)
- [Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer](https://scholariq.org/papers/comparative-cost-effectiveness-of-radiotherapy-among-older-women-with-hormone/)

## Researcher topics

- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Researcher university

- [University Hospitals of Cleveland](https://scholariq.org/institutions/university-hospitals-of-cleveland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.